Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas. Show more
Location: 1751 River Run, Fort Worth, TX, 76107, United States | Website: https://actuatetherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
178.6M
52 Wk Range
$5.47 - $11.99
Previous Close
$8.61
Open
$8.60
Volume
39,108
Day Range
$8.60 - $9.22
Enterprise Value
185.2M
Cash
6.493M
Avg Qtr Burn
-5.678M
Insider Ownership
17.84%
Institutional Own.
54.09%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Elraglusib Details Advanced Salivary Gland Carcinoma | Phase 2 Data readout | |
Elraglusib + gemcitabine/nab-paclitaxel (GnP) Details 1L metastatic pancreatic ductal adenocarcinoma (mPDAC) | Phase 2 Update |